usually also evidence of reduced renal function. Renal morphological changes similar to those produced by gentamicin in rats were observed in human allograft biopsy specimens obtained during gentamicin treatment.
clinical studies of acute myocardial infarction have shown an association between mortality or the incidence of ventricular fibrillation and the use of oral hypoglycaemic agents. 9 We have been impressed by the acceptability to the patient of the relatively intensive dietary management adopted in our study, and if present trends continue a much smaller proportion of our maturity onset diabetic patients will be considered for treatment with oral hypoglycaemic agents. After the six-month assessment only six of our patients were admitted to the second stage of this study and started on an oral hypoglycaemic agent. We do not intend here to analyse this group in detail, but the criterion for advising oral hypoglycaemic treatment was a fasting plasma glucose consistently above 11 mmol/l (200 mg/ 100 ml).
Fasting plasma glucose, which is a relatively unimportant factor in predicting risk of a subsequent cardiovascular event,' 0 showed as good an improvement in the good dieters as in those who co-operated less well. Thus, if plasma glucose alone was used as an index of diabetic control all of these patients might be classified as making a satisfactory response. The significant hyperinsulinaemia and hypertriglyceridaemia in the poor dieters shows that factors other than fasting glucose must be considered in assessing diabetic control in a long-term study. In this initial report these factors have not been affected by any therapeutic regimen other than diet and one foresees the complicated effects of random allocation on the basis of plasma glucose alone of some of these patients to treatment groups with one or other type of oral hypoglycaemic treatment or insulin. Furthermore, the simple fact of real carbohydrate intake as a prime cause of hypertriglyceridaemia in this subgroup of diabetic patients may not always have been rigidly assessed in studies of lipoprotein levels in patients attending a routine diabetic clinic."1 12 Another aspect of our study is the demonstration that the fall in fasting blood glucose which occurs in the first month of dietary treatment is much greater than in any subsequent month, though weight loss proceeds steadily throughout the first six months (except where interrupted by the 200-g carbohydrate intake before the second G.T.T., which itself indicates the overall degree of dietary restriction attained for the rest of the time). This is in keeping with the concept that carbohydrate restriction rather than weight loss is the determining factor in the control of the diabetic state.13
Dr. E. Journal, 1975, 3, 278-281 Summary Renal damage was assessed by measuring urinary enzyme excretion in 180 patients with renal allografts. Thirty-six of these patients were studied during 53 courses of treatment with antimicrobial agents which had begun when renal function was stable. Gentamicin was the only antimicrobial agent which was associated with an increase in urinary enzyme activity. There was
Introduction
The activity of certain urinary 3-glycosidases is a sensitive indicator of renal cell damage. Increased urinary activity of N-acetyl P-D-glucosaminidase (NAG) and P-galactosidase (GAL) have been found in patients with renal disease.''3 Some workers have noted an increase in urinary NAG activity during rejection of renal allografts.4 5 Increased urinary activity of these enzymes indicates renal injury but not the cause of injury. During a 15-month study of 180 patients with renal allografts the administration of gentamicin was always followed by a rise in urinary enzyme activity within three days of the start of treatment. The effect of gentamicin on the excretion of urinary enzymes and renal morphology in rats was therefore studied. At doses of 5 mg Kg-' day-' increased excretion of urinary enzymes and renal morphological changes were found.6 Kosek et al.7 noted renal morphological changes in rats given doses as low as 1 mg kg-' day-'. We describe here the effects of gentamicin treatment on patients with renal allografts.
Patients and Methods
Enzyme assays were performed on fresh mid-stream specimens of urine within six hours of collection. It was unnecessary to dialyse or centrifuge the urine before enzyme assay.4 Fluorimetric methods were used to determine the activity of NAG,8 GAL,9 and alkaline phosphatase,' 0 using urine samples diluted twenty fold and the appropriate 4-methylumbelliferyl substrates. Enzyme activity was expressed per mg of urinary creatinine to account for the effect of varying rates of urine flow at the time of collection.3 Creatinine concentration was measured by the alkaline picrate method modified for autoanalyser (Technicon).
During a 15-month study of 180 patients with renal allografts urinary enzyme activity was measured during and either before or after 171 courses of treatment with antimicrobial agents in 63 patients. At the time of administration of many of these agents, however, there were other possible causes for changes in renal function and increased enzyme excretion, such as septicaemia, hypotension, allograft rejection, or urinary fistulae. Such cases were therefore excluded and we studied the effects of treatment in 36 patients receiving 53 courses of antimicrobial agents when there was no other recognized factor which could have caused an increase in urinary enzyme activity ( (gentamicin alone (six); gentamicin and clindamycin (one)) could be compared only with the enzyme activity in the week before (six) or the week after (one) gentamicin. The ratio of the mean NAG activity during to the mean NAG activity before gentamicin in the six courses varied from 1 5 to 5 6. In the week after the seventh course of gentamicin the mean urinary NAG activity was half the value during treatment. showed the light microscopic changes of tubular necrosis or of-acute rejection. Thin sections from the Epon-embedded tissue were stained with 1% toluidene blue before preparation of the blocks for ultra-thin sectioning. These thin sections showed occasional dark granules in the cytoplasm of proximal tubular epithelium similar to those seen in the epithelium of rats treated with gentamicin. Electron microscopy showed that these dark granules corresponded with dense laminated bodies found throughout the cytoplasm of the proximal tubular cells (fig. 2) . Similar laminated bodies were also found in the tubular lumen. Discussion Gentamicin was isolated by Weinstein et al. from two previously undescribed micro-organisms of the genus micromonospora."1 Early studies showed that it had a nephrotoxic action in animals but only in high doses."2 13 More recently, however, morphological changes have been shown in the kidneys of rats given low doses of gentamicin. 6 Flandre and Damon13 noted that gentamicin caused more severe damage in rats with surgicallyinduced renal insufficiency than in rats with normal renal function, which may have some bearing on our findings in patients with renal allografts. Several authors have found little or no evidence of gentamicin nephrotoxicity.14-17 Leigh18 and Taguchi and Siddiquuiel 9 noted no renal toxicity when gentamicin was used in patients with renal transplants. Nevertheless, evidence of mild renal impairment has been reported in patients treated with gentamicin,80-25 and some workers have reported more serious disturbances of renal function, sometimes when gentamicin has been given with cephalosporins.26 '1 The urinary activity of one or more enzymes rose considerably in all patients treated with gentamicin in our study. NAG and GAL are lysosomal enzymes found in abundance in the renal tubules whereas alkaline phosphatase is located mainly on the brush border of the proximal renal tubules. The urinary enzyme increase appeared consistently within three days of the start of treatment and fell towards pre-treatment levels a week after treatment stopped. No such increase in urinary enzyme activity was noted during treatment with any other antimicrobial agent. The size of the increase in urinary enzyme activity in patients given gentamicin and a cephalosporin was similar to that observed when gentamicin alone was given.
The causes of changes in renal function in patients with renal allografts are often difficult to determine; rejection of the graft must always be considered. During 15 out of 20 courses of gentamicin serum creatinine rose, and during 1 1 out of 17 courses urinary protein excretion increased. Serum creatinine and urinary protein returned towards pre-gentamicin levels during treatment in only a minority of cases. Usually, levels returned to normal the week after stopping treatment. Our evidence suggests that these functional changes were due to gentamicin.
The morphological changes seen in rats6 7 given gentamicin at doses as low as 1 mg kg-' day-' were also noted in biopsy specimens obtained from patients with renal allografts during gentamicin treatment. Tubular necrosis was not produced in any of our cases, and the observed reduction in urinary enzyme activity after gentamicin treatment implies that the damage was reversible in most cases. Nevertheless, deteriorating renal function during treatment necessitated graft nephrectomy in two patients and haemodialysis in another two. In rats withdrawal of gentamicin results in some tubular regeneration even after high doses of the antibiotic,6 but caution should be exercised when giving this antibiotic, particularly to patients with renal allografts or renal disease. More specifically, an increase in urinary enzyme activity should not be interpreted as indicating rejection of a renal allograft when the patient is also receiving gentamicin.
